stockrowBiogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.
- Revenue
- +10.6%
- EPS
- −104.4%
- Free cash flow
- −69.3%
- Total debt
- +16.0%
Quarter to September 2026, against a year earlier
Follow BIIB
Alert me
Biogen Inc. (BIIB) Revenue growth
Biogen Inc.'s revenue growth over the twelve months to 30 September 2026 was 2.30%, up 0.1 percentage points from fiscal 2025 (2.22%). Over the past ten years it has ranged from −18.3% (fiscal 2021) to 10.9% (fiscal 2015); the current reading is higher than 55% of that period. That is below the Drug Manufacturers General industry median of 6.72% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 2.22% | 3.84 |
| FY2024 | −1.62% | 1.70 |
| FY2023 | −3.32% | 4.04 |
| FY2022 | −7.36% | 10.96 |
| FY2021 | −18.3% | (11.83) |
| FY2020 | −6.49% | (13.37) |
| FY2019 | 6.88% | (2.73) |
| FY2018 | 9.61% | 2.40 |
| FY2017 | 7.21% | 0.85 |
| FY2016 | 6.36% | (4.57) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 10.6% | 7.21 |
| Jun 2026 | 3.42% | 1.49 |
| Mar 2026 | 1.93% | 9.07 |
| Dec 2025 | −7.14% | (9.93) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| SNY Sanofi compare | 26.3% |
| NVO Novo Nordisk A/S compare | 13.2% |
| AMGN Amgen Inc. compare | 8.15% |
| AZN AstraZeneca PLC compare | 7.32% |
| GSK GSK PLC Sponsored ADR compare | 6.90% |
| GILD Gilead Sciences, Inc. compare | 6.54% |
| BMY Bristol Myers Squibb Company compare | 4.16% |
| BIIB Biogen Inc. | 2.30% |
| PFE Pfizer Inc. compare | 1.34% |
| Drug Manufacturers General industry median | 6.72% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement